NOVAVAX INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
NOVAVAX INC (NVAX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 0.90% for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2021-05-10
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-03-31 was 0.90%, a 40.00% decline year-over-year.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2020-03-31 was 1.50%, a 42.31% decline year-over-year.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2019-03-31 was 2.60%, a 2.36% increase year-over-year.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2018-09-30 was 2.86%, a 63.43% increase year-over-year.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2018 was 3.10%, a 32.48% increase from fiscal 2017.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 2.34%, a 31.46% increase from fiscal 2016.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2016 was 1.78%, a 16.43% decline from fiscal 2015.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2015 was 2.13%, a 4.05% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2021-03-31 | 0.90% 10-Q · filed 2021-05-10 | |||
| 2020-03-31 | 1.50% 10-Q · filed 2021-05-10 | |||
| 2019-09-30 | 2.60% 10-Q · filed 2020-11-10 | |||
| 2019-03-31 | 2.60% 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | 3.10% 10-K · filed 2019-03-18 | |||
| 2018-09-30 | 2.86% 10-Q · filed 2018-11-07 | 2.86% 10-Q · filed 2018-11-07 | ||
| 2018-06-30 | 2.74% 10-Q · filed 2018-08-08 | 2.74% 10-Q · filed 2018-08-08 | ||
| 2018-03-31 | 2.54% 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | 2.34% 10-K · filed 2019-03-18 | |||
| 2017-09-30 | 1.75% 10-Q · filed 2018-11-07 | 2.34% 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | 1.71% 10-Q · filed 2018-08-08 | 2.34% 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | 2.34% 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | 1.78% 10-K · filed 2019-03-18 | |||
| 2016-09-30 | 1.09% 10-Q · filed 2017-11-07 | 1.70% 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | 1.09% 10-Q · filed 2017-08-08 | 1.70% 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | 1.70% 10-Q · filed 2017-05-08 | |||
| 2015-12-31 | 2.13% 10-K · filed 2018-03-14 | |||
| 2015-09-30 | 1.39% 10-Q · filed 2016-11-09 | 2.13% 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | 2.13% 10-Q · filed 2016-08-09 | 2.13% 10-Q · filed 2016-08-09 | ||
| 2014-12-31 | 2.22% 10-K · filed 2017-02-27 | |||
| 2014-09-30 | 1.51% 10-Q · filed 2015-11-09 | 2.22% 10-Q · filed 2015-11-09 | ||
| 2014-06-30 | 1.39% 10-Q · filed 2015-08-10 | 2.22% 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | 2.22% 10-Q · filed 2015-05-07 | |||
| 2013-12-31 | 1.36% 10-K · filed 2016-02-29 | |||
| 2013-09-30 | 1.36% 10-Q · filed 2014-11-06 | 1.36% 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | 0.96% 10-Q · filed 2014-08-07 | 1.34% 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | 1.34% 10-Q · filed 2014-05-08 | |||
| 2012-12-31 | 1.54% 10-K · filed 2015-02-27 | |||
| 2012-09-30 | 1.54% 10-Q · filed 2013-11-12 | |||
| 2012-06-30 | 1.54% 10-Q · filed 2013-08-08 | |||
| 2012-03-31 | 1.54% 10-Q · filed 2013-05-09 | |||
| 2011-12-31 | 1.91% 10-K · filed 2014-03-12 | |||
| 2011-09-30 | 0.68% 10-Q · filed 2012-11-09 | 1.91% 10-Q · filed 2012-11-09 | ||
| 2011-06-30 | 1.91% 10-Q · filed 2012-08-09 | 1.91% 10-Q · filed 2012-08-09 | ||
| 2010-12-31 | 2.89% 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |